Translation and Validation of the Greek Version of a Questionnaire Measuring Patient Views on Participation in Clinical Trials

Dimitrios Karampatakis  
Aristotle University  

Angeliki Kakavouli-Doudos  
Aristotle University  

Panagiotis Oikonomidis  
Aristotle University  

Polychronis Voultsos (pvoultsos@auth.gr)  
Aristotle University  

Research Article

Keywords: Clinical trial participation, questionnaire / scale, Barriers, Facilitators, Greece / Greek

DOI: https://doi.org/10.21203/rs.3.rs-569599/v1

License: This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License
Abstract

Background

The increasing number of clinical research opportunities requires increasing numbers of participants in clinical trials. However, it may become increasingly problematic, as protocols have become increasingly complex. Better understanding of patients’ attitudes towards their potential participation in clinical trials is essential for developing effective clinical trial recruitment strategies. In Greece, limited research has been conducted on this topic so far. This study aims to contribute to filling this gap.

Methods

A cross-sectional study was conducted. Purposive sampling was used to select participants. The Greek version of a recently developed questionnaire measuring patient views on participation in clinical trials, a 27-item scale distributed into four factors, was tested. In addition, participants were asked to provide information regarding their socio-demographics. A demographic comparison was conducted.

Results

The four-factor solution derived in our study consisted of the same 27 items and it was different from the six-factor solution that Arnetz et al. proposed. The factors risks and benefits, that consisted of 5 and 3 items respectively in the six-factor solution, were merged into one factor that consisted of 10 items in the four-factor solution. The four factors produced were Risks and benefits (ten items, $\alpha = 0.867$), Patient’s expectations (six items, $\alpha = 0.864$), Patient’s participation (five items, $\alpha = 0.827$), and Cost and convenience (five items, $\alpha = 0.770$). We found that demographic factors did not impact patients’ opinions about clinical trials participation, except for gender. The participants reported as important for participating in clinical trial: receiving clear and adequate information (95.5%) and being given the opportunity to ask questions (97.8%), take part in discussions regarding their own treatment (94.6%), and voice their concerns and opinions (91.1%). As factors strongly associated with participants’ willingness to participate in a clinical trial were reported: concerns about the risks of being in a clinical trial (87.5%), the possible side effects of clinical trials (86.3%), the type of treatment given in a clinical trial (83.7%), and whether participation would improve their quality of life (QoL) (81.5%).

Conclusion

The preliminary validation of the Greek version of the questionnaire measuring patient perceptions and expectations of participating in clinical trials demonstrated acceptable validity and reliability and could be further tested in larger samples. The findings that emerged from this study are in line with previous literature.
Recruitment of patients for participation in randomized controlled clinical trials may be challenging, causing delays in trials and hence boosting their costs [1]. It is indicative that fewer than 1 in 20 adult cancer patients enroll in cancer clinical trials. Importantly, “barriers to trial participation are structural, clinical, and attitudinal, and differ according to demographic and socioeconomic factors” [2, 3]. The workload and costs of clinical trials may be profoundly affected by these barriers. For instance, trials may close prematurely or take a longer time to complete [4].

A variety of factors have been cited in the literature as factors affecting the patient’s willingness to participate in clinical trials. For potential participants, barriers may be frequent because of “ethical concerns about randomized trials in general and the additional requirements of informed consent” [5]. For instance, the literature suggests that not only altruism but also self-interest may be the motivating factor for participation [6]. Furthermore, factors that have been associated with patient participation include communication with providers and family members, preference for alternative treatments, convenience, medical history, and insurance [7]. Note that, as trials are becoming increasingly complex (including translational research), many new factors have been emerged as barriers for patients to participate in clinical trials. For instance, one third of older adults in England has difficulty in reading and understanding basic health-related information, and patients can have misconceptions about research-related issues, such as the goals of the clinical trial, the risk of side effects and the likelihood of personal benefits [4, 8–10]. Moreover, mandatory research biopsies may discourage patients from participating in trials [11, 12]. To successfully conduct a clinical trial, the different attitudes and motivations of participants according to trial type must be considered [13].

However, existing research on patient views on participation in clinical trials is not yet very advanced or broad. Much of it “has focused on cancer patients, while a few studies examined cardiology and heart attack patients or the general public” [7]. However, other medical conditions have remained unexplored. A better understanding of patients’ views of participating in clinical trials would contribute to a better execution of clinical trials. It may facilitate trial recruitment and improve patient satisfaction with the recruitment process [4]. Trial recruitment should be facilitated, provided that a significant percentage of the general population is unlikely to have a negative attitude towards participating in clinical trials. For instance, Comis et al. found that a significant percentage of Americans are willing or inclined (while holding some questions) to participate in a cancer clinical trial [14]. At any rate, incorporating patient views into the patient recruitment process can promote both patient-centered research and clinical trial effectiveness.

The aim of the present study was to translate and validate the Greek version of the questionnaire developed by Arnetz et al. (2019) for measuring patient perceptions and expectations of participating in clinical trials. We obtained permission from the authors to conduct this study.

In the absence of adequate specific empirical knowledge about this topic in Greece, we carried out a prospective patient survey using the translated questionnaire to gain a better understanding of patients’ willingness and motivations for participating in clinical trials, and their opinion on trial information and
the consent process. The translated questionnaire was administered online, given current restrictions due to COVID-19, with the participation of 313 individuals. All reasonable precautions were taken to ensure the construction of a randomized sample, without any selection or self-selection bias, or any other type of bias.

Materials And Methods

The questionnaire

To further expand the usage of the pilot questionnaire developed by Arnetz et al. (2019) for measuring patient perceptions and expectations of participating in clinical trials, we attempted to translate, adapt, and validate that questionnaire in the Greek context, after having conducted a literature review on earlier research on patient perceptions of involvement in medical care, in general and especially in Greece.

The translated and adapted to the Greek context questionnaire for measuring patient perceptions and expectations of participating in clinical trials was anonymously administered, with four response options per item (strongly disagree, partly disagree, strongly agree, partly agree OR very important, important, slightly important, unimportant). Demographic data was also recorded, including gender (M/F), age (years), educational background, race, marital status, professional situation, the participants’ physical and mental health status, and the participants’ medical history, including if participants had previously already participated in clinical trials.

Translation

The questionnaire was translated according to the Medical Outcomes Trust (1997) criteria. First, three bilinguals carried out translation of the questionnaire from English into Greek. After consensus had been reached within the group of translators, two other bilinguals translated it back from Greek into English. The translated version was reviewed for item relevance and content validity by a panel of researchers experienced in quantitative research as a type of empirical investigation, at the School of Medicine (Faculty of Health Sciences, Aristotle University). Some slight changes were made to better adapt the questionnaire to the Greek context. Then, the questionnaire was reviewed by 20 senior medical students to locate any difficulties in understanding the meaning of the questions. Please note that in this paper (including the Additional Files), the items of the questionnaire have been translated from Greek (as presented in the Greek version of the questionnaire) into English.

Participants

Patients for this study were recruited online, from 13 different districts of Greece, via links provided to patients that were visiting Greek clinic and hospital websites, in order to discuss a medical condition with a clinic or hospital representative or book an examination appointment for them or a relative. Data was collected from the visitors of websites and customer portals of large clinics and hospitals in Greece. All participants were provided with detailed information and clarifications, regarding the purpose of the study, via both email and phone conversations to ensure compliance with all ethical considerations [15].
Data collection for the questionnaire took place between January and March 2021, and 313 patients were recruited in total. All respondents willing to participate received either a EUR 2.5 compensation or a EUR 3.0 Amazon gift card for their participation. The responses were anonymized and explicit consent to participate was provided by all participants to proceed with filling in the questionnaire. Participants were assured that their personal data would be kept confidential and separate from their questionnaire responses.

**Statistical analysis**

Data was analyzed using IBM SPSS Statistics for Windows, version 25.0. (Armonk, NY: IBM Corp). The agreement between responses at two time points was examined utilizing RStudio [16] and raters package [17]. Means and standard deviations were calculated for interval data and, median and interquartile range for ordinal data. Test-retest reliability was evaluated by administering the questionnaire to 35 participants twice, within an interval of two weeks. Since data obtained from participants’ responses were ordinal, the non-parametric Wilcoxon test was conducted for examining the differences between the responses at each time point. Agreement between responses at the two time points was evaluated by the modified Fleiss’ Kappa, [18] since an imbalance distribution of responses was involved.

To determine the factor structure of the questionnaire, an exploratory factor analysis (EFA) was conducted using Principal Component Analysis (PCA) with Varimax rotation.

Preliminary analyses were implemented for considering the appropriateness of EFA. In particular, the Kaiser-Meyer-Olkin (KMO) measure of sampling adequacy was computed for quantifying the degree of intercorrelations among the variables and the appropriateness of factor analysis [19]. Hutcheson et al. (1999) consider values between 0.5 and 0.7 as mediocre, values between 0.7 and 0.8 as good, values between 0.8 and 0.9 as great, and values greater than 0.9 as superb [20]. The Bartlett's test of sphericity was conducted to examine the correlation among the items [21]. To justify factor analysis, KMO values should exceed 0.60 [22] and Bartlett's test of sphericity should be significant. The Determinant was computed for testing the presence of multicollinearity with values less than 0.0001 to be considered acceptable (no multicollinearity).

The Kaiser's criterion [23] and scree plot [24] were utilized for determining the number of factors to extract at the initial stage of the process. Different factor structures from several trial solutions were compared, mainly by considering the proportion of total explained variance, the factor loadings and their interpretability in order to arrive at the best representation of the data.

Regarding the factor loadings, Hair et al provide guidelines for practical significance, which indicate that a factor loading of ± 0.3 means that the item is of minimal significance, ± 0.4 indicates it is more important and ± 0.5 indicates the factor is significant [25]. Statistical significance of factor loadings was based on the sample size, with a sample size of 200–300 participants to require a factor loading from 0.29 to 0.38 [26]. Therefore, the final factor solution required a minimum factor loading of 0.4 (absolute value). The proportion of the total variance explained by the retained factors should be at least 50% [27].
Reliability of each factor was assessed by the Cronbach's alpha, a measure of internal consistency [28]. Values greater than 0.7 indicate a reliable factor [29].

Associations and correlations were investigated between the four factors and participants' characteristics, such as, gender, age, education, marital status and whether participants took part in a medical research or clinical trial in the past. The values of the factors were compared between two groups of participants applying Mann-Whitney test, and correlations were investigated computing Spearman's correlation coefficient [30].

Statistical significance was set at 5% (p < .05).

**Results**

The sample comprised 313 participants, 156 (49.8%) females and 157 (50.2%) males, aged between 18 and 76 years (M = 43.9, SD = 14.1). The participants were recruited from 13 districts of Greece and filled in the survey online.

**Test-retest reliability**

Thirty-five participants completed the questionnaire in test and retest mode two weeks later. Wilcoxon tests showed no significant differences between the two tests (Supplementary Table 1) [All tables are mentioned in the Supplementary Material-Additional File 2 by their number]. The modified Fleiss' kappa statistic (s*) indicated substantial to almost perfect agreement (0.61-1.00) for 22 out of 27 questions and moderate agreement (0.41–0.60) to 5 out of 27 questions (Supplementary Table 1). Overall, test-retest results indicated reliability of the questionnaire.

**Preliminary analysis for EFA**

Exploratory factor analysis (EFA) was conducted on the 27 items in the questionnaire and 6 factors were derived based on Kaiser's criterion (eigenvalues greater than or equal to 1). The KMO measure of sampling adequacy was 0.898 and Bartlett's test of sphericity was significant ($\chi^2(351) = 3917.3, p < .001$), indicating that factor analysis was appropriate for this data. The Determinant was equal to 0.00002 > 0.00001 suggesting no multicollinearity. Taken together the results indicated that all 27 items in the questionnaire were suitable for inclusion in factor analysis.

**Initial factor analysis**

Following the Kaiser's criterion, EFA resulted in a six-factor solution that accounted for 62.2% of total variance. There were two issues regarding this solution. First, there were two out of six factors with only two items loaded on each one of them. Second, examination of the scree plot (Supplementary Fig. 1) [Supplementary Material-Additional File 1] showed a sharp drop in eigenvalues from one to three factors and a slight drop from the fourth to the fifth factor. Since, Kaiser's criterion and scree plot suggested a different number of factors, EFA was re-applied for extracting five, four or three factors. The criteria for
selecting one out of these three solutions were based on factor loadings, proportion of total explained variance and interpretability of the final rotated solutions.

The five-factor solution accounted for 58.2% of total variance, all factor loadings were above 0.4 and there were four items with cross-loadings above 0.4 on a second factor. The four-factor solution accounted for 54.0% of total variance, one factor loading was below 0.4 and there was one item with cross-loadings above 0.4 on a second factor. The three-factor solution accounted for 49.0% of total variance, all factor loadings were above 0.4 and there were four items with cross-loadings above 0.4 on a second factor. Regarding the interpretability, the four-factor solution identified factors that were fairly interpretable, while five-factor and three-factor solutions identified three and one interpretable factor, respectively. Based on the above findings, the four-factor solution was preferred and EFA was re-applied for extracting four factors after excluding from the sample the item with a loading less than 0.4 (item 24).

Final Factor analysis

The KMO measure of sampling adequacy was 0.901 and Bartlett’s test of sphericity was significant \( \chi^2(325) = 3810.9, p < .001 \), indicating adequate factorability of the items. The total explained variance was 55.3%. The first factor, accounting for 16.2% of the total variance, was focused on patient expectations from clinical trials. The second factor, the risks and benefits of the treatment in clinical trials accounted for 15.3% of the total variance, while the third factor related to patients’ participation in clinical trials, and accounted for 12.3% of the total variance. The final factor, accounting for 11.6% of the total variance, was focused on cost and convenience of clinical trials.

The results of EFA are presented in the Supplementary Table 2 along with the assigned labels to factors. All loadings below 0.4 were suppressed. According to the results of EFA presented in the Supplementary Table 2, three out of four factors comprised items with loadings greater than 0.5.

Internal consistency

All factors were considered reliable, with values of Cronbach’s alpha ranging from 0.770 to 0.867, and item-total correlations above 0.3 (Supplementary Table 3).

Factor exploratory analysis and statistical significance

Exploratory factor analysis was conducted to determine the factor structure of the questionnaire and four factors were derived, namely, (i) patient expectations, (ii) risks and benefits, (iii) patient participation, and (iv) cost and convenience.

In the study of Arnetz et al. (2019), the pilot questionnaire consisted of 30 items and it was delivered to 53 patients. The authors derived a six-factor solution that encompassed factors concerning motivation, risks of participation, benefits of participation, understanding the purpose, cost/convenience, and contribution to health improvement. The main questionnaire of the study consisted of 27 items and it was delivered to 55 patients. The factor solution was not the same with the one derived in the pilot phase.
The four-factor solution derived in our study consisted of the same 27 items and it was different from the six-factor solution that Arnetz et al. proposed. The factors risks and benefits, that consisted of 5 and 3 items respectively in the six-factor solution, were merged into one factor that consisted of 10 items in the four-factor solution. There were 7 common items in the two solutions. Also, the factor cost/convenience was almost the same in both solutions, with the four-factor solution comprising one more item than the six-factor solution. The remaining factors were significantly different between the two solutions.

Across the four factors formed (i.e. (i) patient expectations, (ii) risks and benefits, (iii) patient participation, and (iv) cost and convenience), the percentage of participants who fully or partially agreed differs statistically significantly from the corresponding percentage of those who partially or completely disagreed. This provides confidence on the validity of the results, and the recognition of the most crucial elements for each factor. Among different demographic characteristics, the most crucial, statistically significant differences were related to the participants’ gender, with statistically significant differences of views between men and women observed in most factors.

For factor (i) patient expectations (Supplementary Table 16), for each of the 5 items of the questionnaire included in this factor, the percentage of participants who fully or partially agreed differs statistically significantly from the corresponding percentage of those who partially or completely disagreed (p < 0.05).

Also, the statement that the patient has the ability to ask questions (the highest percentage of agreement) shows a significantly higher degree of agreement (Z = -4.888, p < 0.001) than the statement that the patient receives clear information (the second higher agreement rate), providing confidence on correctly identifying the most significant element of this factor.

For factor (ii) risks and benefits (Supplementary Table 17), for each of the 8 questionnaire items included in this factor, once again the percentage of participants who consider the respective issues as very or quite important differs statistically significantly from the corresponding percentage of those who consider them as little or not at all important (p < 0.05).

However, the issue of risks and side effects that patients may face, which was identified as the most significant element of this factor, does not differ significantly in the degree of importance declared by the participants in the study (Z = -0.784, p = 0.433) from the second and third most important elements. On the other hand, the risks (Z = -6.751, p < 0.001) and the side effects (Z = -6.518, p < 0.001) that patients may face differ significantly in the degree of significance declared with the degree of significance stated on whether the treatment would be provided free of charge. Therefore, this would provide us confidence in assuming that potential expenses are of comparatively lower importance for clinical trial participants.

For factor (iii) patient participation (Supplementary Table 18), for each of the 6 questionnaire items included in this factor, the percentage of participants who consider the respective expectations as very or quite significant differs statistically significantly from the corresponding percentage of those who consider them as little or not at all important (p < 0.05). However, no statistically significant differences
were found between expectations from participation in clinical trials regarding the degree of significance reported \( (p > 0.05) \). Here, a potentially larger sample might be helpful in drawing more definitive results.

Finally, for factor (iv) cost and convenience (Supplementary Table 19), for each of the 6 items of the questionnaire included in this factor, the percentage of participants who consider the respective issues as very or quite important differs statistically significantly from the corresponding percentage of those who consider them as little or not at all important \( (p < 0.05) \).

However, the issue of confidentiality of all personal data and results of the clinical study (most important element) and the issue of possible other costs for participation in this clinical study (second most important element) do not differ significantly in the degree of importance stated by the participants in the study \( (G = -1.467, p = 0.142) \). On the other hand, the issue of confidentiality of all personal data and results of the clinical study \( (Z = -4.420, p < 0.001) \) and the issue of possible other costs for participation in this clinical study \( (Z = -3.480, p = 0.001) \) show a significant difference in the degree of significance declared for the remaining elements of this factor.

**Demographics and demographic comparison**

Participants’ ages ranged from 18 to 76 years \( (M = 43.9, SD = 14.1) \) with 51.4% \( (n = 161) \) identified as female, 48.6% \( (n = 152) \) as male, 63.3% married or partnered, approximately 30% reported living alone (single, divorced or widower), 22.7% reported being retired or not working \( (10.2\% \text{ and } 12.5\% \text{ respectively}) \), 62.6% reported being working or self-employed \( 49.5\% \) \( (n = 155) \) had post-secondary and higher education, \( 32.9\% \) \( (n = 103) \) had secondary education, and \( 13.1\% \) \( (n = 41) \) possessed a Master degree. The vast majority of participants \( (97.8\%) \) identified themselves as white people. Approximately half of the participants \( (47.6\%) \) were not “high-income participants.” The mean of their net personal annual income was lower than 10,000 euros. The percentage of participants reporting net personal annual income ranging from 10,000 euros to 20,000 euros was lower \( (32.3\%) \), with \( 13.1\% \) of participants reporting net personal annual income ranging from 20,000 to 30,000 euros.

The time in minutes that participants were willing to spend for transferring to a research site for study-related procedures ranged from 0 to 400 min \( (M = 32.5, SD = 39.8) \), while on average they were willing to cover a distance of 330 kilometers.

The majority \( (54.6\%) \) of participants indicated that they would choose to go to a research site by car, with \( 21.1\% \) of the participants reporting their preference to go on foot, \( 18.8\% \) by means of public transportation and \( 5.4\% \) on bicycle or motorcycle.

Slightly more than 9 out of 10 participants \( (91.7\%) \) reported having health insurance.

The vast majority of participants \( (80.8\%) \) reported their physical or psychological condition as being in a peak state \( (16.6\%) \), in a very good state \( (32.6\%) \) or just in a good state \( (31.6\%) \), with \( 19.2\% \) of participants reporting their condition as mediocre \( (15.7\%) \) or even bad \( (3.5\%) \).
Furthermore, in our study we found that 6.1% of our respondents had previously participated in a clinical trial, with the 89.5% of them reporting they had received a clear and direct benefit (26.3%) or had rather been benefited (63.2%).

The majority of our participants (61.7%) reported they had never previously taken medications or undergone treatment for any of the diseases mentioned in the Supplementary Table 12, with a lower proportion of participants reporting they had undergone treatment for anxiety (16.0%), hypertension (11.8%), cardiovascular disease (10.9%) and panic attacks (7.3%).

The participants in our study strongly supported the view that participation in clinical trial means that the participants (patients): a) are offered the opportunity to be clearly informed (95.6%) and ask questions (97.8%), b) receive clear and adequate information (95.5%), c) are offered the opportunity to take part in discussions regarding their own treatment and health care (94.6%), d) are offered the opportunity to voice their concerns and opinions (91.1%) and e) are offered the opportunity to become involved in decision making processes regarding their own treatment and health care (85.6%).

Furthermore, our participants were asked about the importance and impact of some factors on their willingness to participate in a clinical trial aiming at curing a disease or eliminating a health-related problem. The elements that were reported as most significant by the greatest proportion of participants were: a) the concerns about the risks of being in a clinical trial (87.5%), b) the possible side effects of clinical trials (86.3%), c) the type of treatment given in a clinical trial (83.7%), d) whether participation would improve their quality of life (81.5%), with only 62.6% of the participants finding very significant the fact that the treatment will be provided free of charge.

Almost all the participants in our study (98.7%) had no difficulty understanding the items of the scale, with 88.2% reporting that the administered scale was not lengthy.

Moreover, the participants in our study were asked about the elements “knowledge / information”, “their expectations towards participation in clinical trials”, “convenience” and “costs / payments.” The factors that were reported as most significant by the greater proportions of participants were: a) the confidentiality of participants’ personal data in the clinical trial and the confidentiality of the results of the clinical trial (68.7%), b) the understanding of the way in which the particular clinical trial might benefit the respondent (67.7%) and other patients at the present time (68.4%), and c) the understanding of the purpose of the particular clinical trial (66.8%), with d) 52.7% of the participants finding very significant the eventual need for a participant to travel to a research site for study-related procedures.

Among different demographic characteristics, the most crucial, statistically significant differences were related to the participants’ gender.

Mann-Whitney tests indicated significant differences between males and females regarding views on the following factors: ii) the risks and benefits (Z = 2.574, p = .010), iii) patient participation (Z = 3.104, p
= .002), and iv) cost and convenience (Z = 3.135, p = .002). Males especially appear to consider the cost and convenience factors less important than females.

Otherwise, none of the four factors demonstrated statistically significant correlation to age, education, or marital status (p > .05). Nevertheless, we do observe some factors emerging from our data analysis as associated with taking a certain stance on the questions included in the administered scale. More precisely, we find that the responding option “strongly agree” received greater score among participants being over 60 years old, being retired or being in married cohabitation, with the participants in very good psychological condition showing a trend towards choosing the responding option “very important.”

For factor (ii) risks and benefits, women consider as more important than men the issue of risks (Z = -2.198, p = 0.028), side effects (Z = -3.343, p = 0.001) and possible discomfort, inconvenience or pain (Z = -3.011, p = 0.003), which they may face in the context of a clinical trial.

For factor (iii) patient participation, women consider it more important than men to understand how the clinical trial could help them personally at the moment (Z = -3.430, p = 0.001) and in the future (Z = -2.900, p = 0.004), to understand the purpose of the clinical trial (Z = -2.956, p = 0.003) and that the clinical study will be part of a broader medical research study (Z = -1.969, p = 0.049).

Finally, for factor (iv) cost and convenience, women consider more important than men the need to travel to participate in the clinical trial (Z = -3.515, p < 0.001) and the assistance of another person to participate in the clinical trial (Z = -3.426, p = 0.001).

Moreover, according to Mann-Whitney results, individuals, who had participated in a medical research or clinical trial, regarded factor (ii) risks and benefits of the treatment in clinical trial (Z = 2.570, p = .010) and factor (iv) cost and convenience of clinical trials (Z = 2.936, p = .003) as less important than individuals who had not participated in a medical research or clinical trial in the past. This clearly indicates the importance of educating patients on the benefits of clinical trials, as well as providing them with clear information at the outset, to clarify their expectations.

**Discussion**

We found that demographic factors did not impact patients’ opinions about clinical trials participation, with the exception of gender differences. Catania et al. found that demographic factors did not impact patients’ willingness to participate in clinical trials [31]. However, several studies reported several facilitators or significant barriers to trial participation [32, 33]. Among factors affecting people’s willingness to participate in clinical trials the following have been cited: age and race [34, 35, 36, 37], inconvenience to participate [38, 39], economic benefit [40, 41], socio-economic factors [34, 42], education level [34, 41, 43], availability of treatment options, participants’ burden, participants’ health status, racial difference [44], and types of research [45].
Participants’ gender has been cited in literature as a factor affecting people’s willingness to participate in clinical trials [34, 38, 46, 47]. Several studies have reported that women were less likely than men to enroll in clinical trials [37, 48–51]. However, some studies found higher clinical trial participation rates among women [52, 53], with a study reporting “no evidence of any systematic under-representation of women in clinical trials” [54]. A population-based study found no evident gender differences in clinical trial participation [38].

Sufficient and clear information, discussion with researchers, possible side effects in clinical trials and potential QoL-related benefits of participating in clinical trials have been reported as factors that are very important for participating in clinical trials.

**Information**

Sufficient and clear information is a strong motivation to participating in a clinical trial whereas lack of information or explanation is a strong motivation to refuse participation in a clinical trial [55, 56]. While it is paramount to ensure that patients can make an adequately informed decision about participation in clinical trials [57], the consent to participate on a clinical trial often is not adequately informed [34]. In a study conducted by Mowlabaccus and Jodheea-Jutton, 19.1% of the respondents were of the view that participants in clinical trials often are not adequately informed [34]. In a study conducted by Godskesen et al. it has been cited that a minority (20–28 %) of patients felt that the amount of information provided was adequate [9]. Limited previous information about clinical trials is cited as an important barrier to participation [58]. Note, however, that providing adequate information to clinical trial participants is not an easy task. As is the case with patient clinical information, clinical trial information should be concise. Lengthy information can be confusing for patients [59]. Furthermore, trial information should be tailored according to the individual patient’s core values and preferences [60]. Importantly, it has been cited in literature that patients may have misunderstood the purpose of a clinical trial [4, 61] or the potential personal benefit from a clinical trial [62]. Patients who enter quickly into clinical trial registers may not feel that they fully understood the implications of their clinical trial participation [63]. Therefore, patients should be given an adequate time frame to consider the information provided [4]. At any rate, adequate information is a strong factor promoting clinical trial participation. A majority (76%) of the respondents in a survey conducted by Catania et al. “considered that a thorough explanation of toxicity/safety of the proposed treatment would lead them to a more conscious motivation in deciding” [31].

Several studies suggest that patients who participated in clinical trials should be offered the trial results [4, 59, 64–66]. Not receiving results may discourage patients from participating in future trials [64]. The majority of participants in a survey conducted by Jones et al. valued the publication of trial results as either important (36%) or very important (48%). Moreover, a majority (63%) “reported they would be less likely to participate in a trial if investigators had not publicly released results from a prior study”. Importantly, 85% “felt that it was important or very important to receive information about the publication track record of sponsors and investigators during the informed consent process” [57]. In this perspective, Jones et al. state that the public release of trial results may be a factor motivating clinical trial
participation [57]. Interestingly, Cox et al. state that “some individuals desired personal results, others wanted to know the overall findings and many wanted to know both of these things” [66].

Moorcraft et al. arguably state that “the majority of patients feel they should be offered the trial results, not only for their personal interest and satisfaction, but also out of respect for their contribution to the trial” [4]. The potential distress of hearing bad news is not a sufficient reason for not informing trial participants of the trial results [66].

Discussion with researchers

Participating in discussions and engaging in shared decision-making processes may improve the participant–research team relationship by creating a research environment in which the patients feel that they are valued and respected.

Participants’ trust in researchers has been cited in literature as a factor affecting their willingness to participate in clinical trials [4, 9, 14, 59, 62, 67–72]. Trust in researchers is a strong facilitator of clinical trial participation. Catania et al. found that trust in researchers (76%) or in the institute (64%) might be facilitators of participation in clinical trials [31]. Establishing trust in health providers and creating a relationship between participants and recruiters can promote participation in clinical trials [73]. Catania et al. reported that 31% of their respondents were concerned by potential conflicts of interest between participants and researchers. Twenty-eight percent of respondents feared that researchers “were interested only in advancing their own research” [31].

Respondents (28.4%) in a study carried out recently by Mowlabaccus and Jodheea-Jutton raise concerns towards trust in pharmaceutical companies [41]. It seems to be important to participants in clinical trials to be sure that the final beneficiaries of trials are patients rather than commercial pharmaceutical companies [74]. Furthermore, 32.8% of the responders perceived government as an insufficient guarantor of public against unethical clinical research [41]. In the same vein was a study carried out by Burt et al. [75]. Enhancing transparency in the conduction of clinical trials can increase the trust of participants [76]. The same holds true for the procedure of obtaining informed consent [71]. Moreover, researchers’ adherence to research ethics, i.e. maintaining good ethical standards and hence reducing risk, maximizing research benefits, and assuring distributive justice to participants, contributes to promoting participants’ trust to researchers [33]. Conversely, several studies showed that financial conflicts of interest between participants and researchers can undermine participants’ trust in researchers [72, 77–81].

Benefits

Improving participants’ health status is cited as a facilitator of clinical trial participation [41]. Ferrell et al. found that patients inclined to participate “had no other treatment options if they wanted to live longer, or they wanted to help future patients with cancer. Most believed that participation would improve or stabilize their illness and quality of life. They believed that, when the clinical trial ended, there would be new treatments” [82]. Catania et al. found that hope for having one more chance to cure (78%) might be a
facilitator of participation in clinical trials [31]. Moorcraft et al. found that 52% of patients were motivated by a belief that they would receive the best treatment option available, closer monitoring and better quality care [4]. Pride in participating and hope for a better quality of life are motivations to consent to participating in a clinical trial [56]. The aforementioned findings are in line with other studies [9, 10, 14, 59, 62, 68, 69, 83].

**Fears**

Fears of mistreatment, potential side effects from little-known drugs and exploitation have been reported in literature as strong barriers to clinical trial participation [34, 56, 84–88]. More particularly, fears of drug-related side effects have been cited in literature as a major barrier to participating in clinical trials [34, 42, 89]. In a recent study, around 47% of participants were afraid of potential side effects [41]. Catania et al. found that 50% of the respondents in their study were feared of receiving unknown or little-known drugs [31]. Being treated as ‘guinea pigs’ (36%) are reported by the authors as a barrier to participation [31]. In a recent study, 35% of the respondents were feared of being treated as ‘guinea pigs’ [41]. Several participants in a single-center study conducted in the US by Sood et al. felt that their safety (93%) would be ensured to participate in a clinical trial [64].

**Remuneration**

The vast majority of the participants in our study (89.2%) indicated that possible remuneration for participation in clinical trial was viewed as a very or fairly significant factor. Mowlabaccus and Jodheea-Jutton found that 41% of respondents stated that they would be motivated by a payment offer to participate in clinical trials [41]. Walsh and Sheridan found that payment is a strong facilitator of participating in clinical trials [40]. However, Manton et al. reported that participation in clinical trials is motivated not only by financial gains but also by many other motivations, included altruism [39]. Stocks et al. reported that money did not influence participation in clinical trials [90]. Furthermore, in the context of minority participation, remuneration was found to be important to male participants whereas the researcher-participant relationship was important to female participants [91].

**Limitations**

As the data of our survey were collected from 13 different districts of Greece, the demographics of participants may be representative of the general population, at least to a large extent. This can be regarded as a chief strength of the study. In this survey, the respondents (patients) came from a broad range of demographics, such as educational background, age, gender, marital status, employment status. The diversity in our survey may be regarded as one of its strengths. However, while the vast majority of previous studies on the topic of patient views on clinical trial participation have used methods involving disease-specific patient groups (groups of patients with the same or similar diagnosis or symptoms), in our study any given medical condition had an equal probability of being involved. As a consequence, the results from this cross-sectional study were subject to limited disease-related bias compared to other studies involving patients with a particular medical condition. However, as the patients’ views on clinical
trial participation may be strongly affected by their actual medical condition, larger and diverse nationwide samples would enable more robust validity testing of the questionnaire and produce more generalizable results on a national level. At any rate, there is the potential for response bias. Our respondents might be patients with a particular interest in medical research. Furthermore, while the questionnaire covers a broad range of topics, it does not include questions asking “how important it would be to you what is the expected success rate of the trial” or questions exploring respondents’ willingness to participate in a clinical trial, their motives or whether they wish to know their personal (or the overall study) results of trials in which they participated. Moreover, patients’ responses may be influenced by ‘social desirability.’ It is uncertain whether patients’ responses truly reflect their views. These are limitations of our study. Ultimately, consistent with the nature of surveys is the following limitation: Quantitative research cannot capture all dimensions of the phenomenon of interest. When combined with qualitative research studies, qualitative studies may provide much more insightful understanding of patients’ attitudes towards participating in clinical trials. Despite these study limitations, the Greek version of the questionnaire can be useful for measuring the patient views of participation in clinical trials in Greece, where quantifying of these views is in its very infancy.

Conclusion

The preliminary validation of the Greek version of the questionnaire measuring patient perceptions and expectations of participating in clinical trials demonstrated acceptable validity and reliability and could be further tested in larger samples. The findings emerged from this study are in line with previous literature. The four-factor solution derived in our study consisted of the same 27 items and it was different from the six-factor solution that Arnetz et al. proposed. The factors risks and benefits, that consisted of 5 and 3 items respectively in the six-factor solution, were merged into one factor that consisted of 10 items in the four-factor solution, Furthermore, we found that demographic factors did not impact on patients’ opinions about clinical trials participating, with the exception of gender differences. Sufficient and clear information, discussion with researchers, possible side effects in clinical trials and potential QoL-related benefits of participating in clinical trial have been reported as factors that are very important for participating in clinical trials.

Abbreviations

EFA = Exploratory factor analysis

KMO = Kaiser-Meyer-Olkin

PCA = Principal Component Analysis

Declarations

Authors’ contributions
DK and PV developed the study concept and design. All the authors of this manuscript contributed to translating and adapting the questionnaire to the Greek context. DK and PV analysed and interpreted the data. The other co-authors (A K-D and PO) were involved in the data analysis discussions and monitored the process of this study. DK and PV drafted the manuscript, and all authors provided critical revisions for important intellectual content. The study was supervised by DK and PV. All authors read and approved the final manuscript. DK and PV (corresponding author) contributed equally to this paper.

**Acknowledgements**

The authors are grateful to the participants of this study for their collaboration.

**Competing interests**

The authors declare that they have no competing interests.

**Availability of data and materials**

The datasets used and analysed in this study are available from the corresponding author on reasonable request.

**Consent for publication**

Not applicable.

**Ethics approval and consent to participate**

Written informed consent was obtained from participants. Before starting to fill out the questionnaire, each participant was given information on the study, placing great weight on the importance of maintaining confidentiality. This study and consent procedure was approved and monitored by the Research Ethics Review Board of the School of Medicine, Faculty of Health Sciences, Aristotle University of Thessaloniki, Greece (Decision Number: 7/20-4-2021). In addition, we confirm that all methods were performed in accordance with the relevant guidelines and regulations by including a statement in the 'Ethical Approval' heading under 'Declaration' section to this effect.

**Funding**

There are no sources of funding to be declared.

**References**

1. Allison M. Can web 2.0 reboot clinical trials? Nat Biotechnol. 2009;27(10):895–902.
2. Unger JM, Cook E, Tai E, Bleyer A. The Role of Clinical Trial Participation in Cancer Research: Barriers, Evidence, and Strategies. Am Soc Clin Oncol Educ Book. 2016;35:185-98.
3. Mills EJ, Seely D, Rachlis B, Griffith L, Wu P, Wilson K, et al. Barriers to participation in clinical trials of cancer: a meta-analysis and systematic review of patient-reported factors. Lancet Oncol. 2006;7(2):141–8.

4. Moorcraft SY, Marriott C, Peckitt C, et al. Patients' willingness to participate in clinical trials and their views on aspects of cancer research: results of a prospective patient survey. Trials. 2016;17:17.

5. Ellis PM. Attitudes towards and participation in randomised clinical trials in oncology: a review of the literature. Ann Oncol. 2000;11(8):939–45.

6. Nurgat ZA, Craig W, Campbell NC, Bissett JD, Cassidy J, Nicolson MC. Patient motivations surrounding participation in phase I and phase II clinical trials of cancer chemotherapy. Br J Cancer. 2005;92(6):1001-5.

7. Arnetz J, Sudan S, Goetz C, Arnetz B, Gowland L, Manji S, Ghosh S. Preliminary development of a questionnaire measuring patient views of participation in clinical trials. BMC Res Notes. 2019;12(1):667.

8. Joffe S, Cook EF, Cleary PD, Clark JW, Weeks JC. Quality of informed consent in cancer clinical trials: a cross-sectional survey. Lancet. 2001;358(9295):1772–7.

9. Godskesen T, Hansson MG, Nygren P, Nordin K, Kihlbom U. Hope for a cure and altruism are the main motives behind participation in phase 3 clinical cancer trials. Eur J Cancer Care. 2014.

10. Daugherty C, Ratain MJ, Grochowski E, Stocking C, Kodish E, Mick R, et al. Perceptions of cancer patients and their physicians involved in phase I trials. J Clin Oncol. 1995;13(5):1062–72.

11. Agulnik M, Oza AM, Pond GR, Siu LL. Impact and perceptions of mandatory tumor biopsies for correlative studies in clinical trials of novel anticancer agents. J Clin Oncol. 2006;24(30):4801–7.

12. Pentz RD, Harvey RD, White M, Farmer ZL, Dashevskaya O, Chen Z, et al. Research biopsies in phase I studies: views and perspectives of participants and investigators. IRB. 2012;34(2):1–8.

13. Chu SH, Jeong SH, Kim EJ, Park MS, Park K, Nam M, Shim JY, Yoon YR. The views of patients and healthy volunteers on participation in clinical trials: an exploratory survey study. Contemp Clin Trials. 2012 Jul;33(4):611-9.

14. Comis RL, Miller JD, Aldige CR, Krebs L, Stoval E. Public attitudes toward participation in cancer clinical trials. J Clin Oncol. 2003;21(5):830–5.

15. Kummar S., Rubinstein L., Kinders R., Parchment R., Gutierrez M., Murgo A., Ji J., Mroczkowski B., Pickeral O., Simpson M., Hollingshead M., Yang S., Helman L., Wiltreut R., Collins J., Tomaszewski J., Doroshow J. (2008). Phase 0 Clinical Trials: Conceptions and Misconceptions. Cancer J. 2008; 14(3): 133–7.

16. RStudio Team. RStudio: Integrated Development Environment for R. RStudio, PBC, Boston, MA, 2020. Available from: http://www.rstudio.com/ (last access: 6 April 2021).

17. Quatto P, Ripamonti E. raters: A Modification of Fleiss' Kappa in Case of Nominal and Ordinal Variables. R package version 2.0.1. 2014. Available from: https://CRAN.R-project.org/package=raters (last access: 6 April 2021).
18. Marasini D, Quatto P, Ripamonti E. Assessing the inter-rater agreement for ordinal data through weighted indexes. Stat Methods Med Res. 2016 Dec;25(6):2611-33.
19. Kaiser HF. A second generation little jiffy, Psychometrika 1970; 35: 401-415.
20. Hutcheson G, Sofroniou N. The Multivariate Social Scientist SAGE Publications, 1999.
21. Bartlett, M.S. (1954) A Note on the Multiplying Factors for Various Chi Square Approximations. Journal of the Royal Statistical Society 1954; 16: 296-298.
22. Tabachnick BG, Fidell LS. Using multivariate statistics. 7th ed. Boston: Pearson; 2019.
23. Kaiser HF. The Application of Electronic Computers to Factor Analysis, Educational and Psychological Measurement 1960; 20: 141-51.
24. Cattel, R. B. The Scree Test For The Number Of Factors, Multivariate Behavioral Research, 1966; 1:2, 245-76.
25. Hair JF, Black WC, Babin BJ, Anderson RE. Multivariate Data Analysis. Prentice Hall, 7th edition, 2009.
26. Stevens JP. Applied Multivariate Statistics for the Social Sciences, Routledge Academic, 5th edition, 2009.
27. Streiner DL. Figuring out factors: the use and misuse of factor analysis. Can J Psychiatry. 1994;39(3):135-40.
28. Cronbach LJ. Coefficient alpha and the internal structure of tests. Psychometrika 1951; 16: 297-334.
29. Cortina JM. What is coefficient alpha? An examination of theory and applications. Journal of Applied Psychology 1993; 78: 98-104.
30. Field A. Discovering Statistics using SPSS. Sage: London, 2009.
31. Catania C, De Pas T, Goldhirsch A, Radice D, Adamoli L, Medici M, Verri E, Marenghi C, de Braud F, Nolè F. Participation in clinical trials as viewed by the patient: understanding cultural and emotional aspects which influence choice. Oncology. 2008;74(3-4):177-87.
32. Mahmud A, Zalay O, Springer A, Arts K, Eisenhauer E. Barriers to participation in clinical trials: a physician survey. Curr Oncol. 2018;25(2):119-125.
33. Jin H, Cui M, Liu J. Factors affecting people's attitude toward participation in medical research: a systematic review. Curr Med Res Opin. 2020 Jul;36(7):1137-1143.
34. Chu SH, Kim EJ, Jeong SH, Park GL. Factors associated with willingness to participate in clinical trials: a nationwide survey study. BMC Public Health. 2015;15: 10. pmid:25595373
35. Brown DR, Topcu M. Willingness to participate in clinical treatment research among older African Americans and Whites. Gerontologist. 2003 Feb;43(1):62-72.
36. London L, Hurtado-de-Mendoza A, Song M, Nagirimadugu A, Luta G, Sheppard VB. Motivators and barriers to Latinas' participation in clinical trials: the role of contextual factors. Contemp Clin Trials. 2015;40:74-80. doi:10.1016/j.cct.2014.11.013
37. Murthy VH, Krumholz HM, Gross CP. Participation in cancer clinical trials: race-, sex-, and age-based disparities. JAMA. 2004 Jun 9;291(22):2720-6.
38. Davis MM, Clark SJ, Butchart AT, et al. Public participation in, and awareness about, medical research opportunities in the era of clinical and translational research. Clin Transl Sci. 2013;6(2):88–93.
39. Manton KJ, Gauld CS, White KM, Griffin PM, Elliott SL. Qualitative study investigating the underlying motivations of healthy participants in phase I clinical trials. BMJ Open. 2019 Jan 15;9(1):e024224.
40. Walsh E, Sheridan A. Factors affecting patient participation in clinical trials in Ireland: A narrative review. Contemp Clin Trials Commun. 2016;3:23–31. PMID:29736453
41. Mowlabaccus WB, Jodhlea-Jutton A. Participant perception, still a major challenge to clinical research in developing countries-A mixed methods study. PLoS One. 2020 Jul 30;15(7):e0236563.
42. Hussain-Gambles M, Atkin K, Leese B. South Asian participation in clinical trials: the views of lay people and health professionals. Health Policy. 2006;77(2):149–165.
43. Barsdorf NW, Wassenaar DR. Racial differences in public perceptions of voluntariness of medical research participants in South Africa. Social Sci Med. 2005;60(5):1087–1098.
44. Wetherell M. Identities, groups and social issues. Vol. 1. London: Sage Publications; 1996. p. 10.
45. Cottler LB, McCloskey DJ, Aguilar-Gaxiola S, et al. Community needs, concerns, and perceptions about health research: findings from the clinical and translational science award sentinel network. Am J Public Health. 2013;103(9):1685–1692.
46. Cobb EM, Singer DC, Davis MM. Public interest in medical research participation: differences by volunteer status and study type. Clinic Translat Sci. 2014;7(2):145–149.
47. Ewing AT, Erby LA, Bollinger J, et al. Demographic differences in willingness to provide broad and narrow consent for biobank research. Biopreserv Biobank. 2015;13(2):98–106.
48. Parekh A, Fadiran E, Uhl K, et al. Adverse effects in women: implications for drug development and regulatory policies. Expert Rev Clin Pharmacol. 2011;4(4):453–466.
49. Wizemann T, Pardue M. Exploring the biological contributions to human health: does sex matter? J Womens Health Gend Based Med. 2001;10:433–439.
50. Liu KA, DiPietro Mager NA. Women's involvement in clinical trials: historical perspective and future implications. Pharm Pract (Granada). 2016;14(1):708–708.
51. Pinnow E, Sharma P, Parekh A, et al. Increasing participation of women in early phase clinical trials approved by the FDA. Women Health Iss. 2009;19(2):89–93.
52. Galea S, Tracy M. Participation rates in epidemiologic studies. Ann Epidemiol. 2007;17(9):643–653.
53. Heerman WJ, Bennett WL, Kraschnewski JL, et al. Willingness to participate in weight-related research as reported by patients in PCORnet clinical data research networks. BMC Obes. 2018;5(1):10.
54. Labots G, Jones A, de Visser SJ, Rissmann R, Burggraaf J. Gender differences in clinical registration trials: is there a real problem? Br J Clin Pharmacol. 2018 Apr;84(4):700–707.
55. Baquet CR, Commiskey P, Daniel Mullins C, Mishra SI. Recruitment and participation in clinical trials: socio-demographic, rural/urban, and health care access predictors. Cancer Detect Prev.
56. Guedj M, Ballester S, Kamar N, Rostaing L, Donckier V, Goldman M, Cambon-Thomsen A. Patients' motives for consenting or refusing to participate in a clinical trial in organ transplantation. Clin Transplant. 2013 Sep-Oct;27(5):724-31.

57. Jones CW, Braz VA, McBride SM, Roberts BW, Platts-Mills TF. Cross-sectional assessment of patient attitudes towards participation in clinical trials: does making results publicly available matter? BMJ Open. 2016 Nov 24;6(11):e013649.

58. Clark LT, Watkins L, Piña IL, Elmer M, Akinboboye O, Gorham M, Jamerson B, McCullough C, Pierre C, Polis AB, Puckrein G, Regnante JM. Increasing Diversity in Clinical Trials: Overcoming Critical Barriers. Curr Probl Cardiol. 2019 May;44(5):148-172.

59. Loco L, Smith L. Personal experiences of taking part in clinical trials – a qualitative study. Patient Educ Couns. 2011;84(3):303–9. doi: 10.1016/j.pec.2011.06.002.

60. Milligan E and Jones J. Rethinking Autonomy and Consent in Healthcare Ethics. In: Bioethics: Medical, Ethical and Legal Perspectives (Ed. P.A. Clark), Charter 2, 2017, In Tech Open, pp: 21-38.

61. Horng S, Emanuel EJ, Wilfond B, Rackoff J, Martz K, Grady C. Descriptions of benefits and risks in consent forms for phase 1 oncology trials. N Engl J Med. 2002 Dec 26;347(26):2134-40.

62. Garcea G, Lloyd T, Steward WP, Dennison AR, Berry DP. Differences in attitudes between patients with primary colorectal cancer and patients with secondary colorectal cancer: is it reflected in their willingness to participate in drug trials? Eur J Cancer Care. 2005;14(2):166–70. doi: 10.1111/j.1365-2354.2005.00535.x

63. Stryker JE, Wray RJ, Emmons KM, Winer E, Demetri G. Understanding the decisions of cancer clinical trial participants to enter research studies: factors associated with informed consent, patient satisfaction, and decisional regret. Patient Educ Couns. 2006;63(1–2):104–9. doi: 10.1016/j.pec.2005.09.006.

64. Sood A, Prasad K, Chhatwani L, Shinozaki E, Cha SS, Loehrer LL, et al. Patients’ attitudes and preferences about participation and recruitment strategies in clinical trials. Mayo Clin Proc. 2009;84(3):243–7. doi: 10.4065/84.3.243.

65. Shalowitz DI, Miller FG. Communicating the results of clinical research to participants: attitudes, practices, and future directions. PLoS Med. 2008;5(5) doi: 10.1371/journal.pmed.0050091.

66. Cox K, Moghaddam N, Bird L, Elkan R. Feedback of trial results to participants: a survey of clinicians’ and patients’ attitudes and experiences. Eur J Oncol Nurs. 2011;15(2):124–9. doi: 10.1016/j.ejon.2010.06.009.

67. Shah JY, Phadtare A, Rajgor D, et al. What leads Indians to participate in clinical trials? A meta-analysis of qualitative studies. PLoS One. 2010;5(5):e10730.

68. Jenkins V, Fallowfield L. Reasons for accepting or declining to participate in randomized clinical trials for cancer therapy. Br J Cancer. 2000;82(11):1783–8. doi: 10.1054/bjoc.2000.1142.

69. Gayet-Ageron A, Rudaz S, Perneger T. Study design factors influencing patients' willingness to participate in clinical research: a randomised vignette-based study. BMC Med Res Methodol. 2020
71. Shaya FT, Gbarayor CM, Huiwen KY, et al. A perspective on African American participation in clinical trials. Contemp Clin Trials. 2007;28:213–217.
72. Liu HE, Li MC. Factors influencing the willingness to participate in medical research: a nationwide survey in Taiwan. Peer J. 2018;6:e4874.
73. Ma GX, Seals B, Tan Y, Wang SY, Lee R, Fang CY. Increasing Asian American participation in clinical trials by addressing community concerns. Clin Trials. 2014 Jun;11(3):328-335.
74. Spector-Bagdady K, De Vries RG, Gornick MG, et al. Encouraging participation and transparency in Biobank research. Health Affairs. 2018;37(8):1313–1320.
75. Burt T, Dhillon S, Sharma P, Khan D, MV D, Alam S, et al. PARTAKE Survey of Public Knowledge and Perceptions of Clinical Research in India. Diemert DJ, editor. PLoS One. 2013;8: e68666. pmid:23874712
76. Lassman SM, Shopshear OM, Jazic I, Ulrich J, Francer J. Clinical trial transparency: a reassessment of industry compliance with clinical trial registration and reporting requirements in the United States. BMJ Open. 2017;7: e015110. pmid:28942418
77. Aitken M, Cunningham-Burley S, Pagliari C. Moving from trust to trustworthiness: experiences of public engagement in the Scottish Health Informatics Programme. Sci Public Policy. 2016;43(5):713–723.
78. Caulfield T, Einsiedel E, Merz JF, et al. Trust, patents and public perceptions: the governance of controversial biotechnology research. Nat Biotechnol. 2006;24(11):1352–1354.
79. Critchley CR, Bruce G, Farrugia M. The impact of commercialisation on public perceptions of stem cell research: exploring differences across the use of induced pluripotent cells, human and animal embryos. Stem Cell Rev and Rep. 2013;9(5):541–554.
80. DeAngelis CD. Conflict of interest and the public trust. Jama. 2000;284(17):2237–2238.
81. Gatter R. Walking the talk of trust in human subjects research: the challenge of regulating financial conflicts of interest. Emory Law J. 2003;52(1):327–401.
82. Ferrell B, Williams AC, Borneman T, Chung V, Smith TJ. Clinical Trials: Understanding Patient Perspectives and Beliefs About Treatment. Clin J Oncol Nurs. 2019 Dec 1;23(6):592-598.
83. Raftery J, Kerr C, Hawker S, Powell J. Paying clinicians to join clinical trials: a review of guidelines and interview study of trialists. Trials. 2009;10:15.
84. González HL, Palencia AP, Umaña LA, Galindo L, Villafrade M LA. Mediated learning experience and concept maps: a pedagogical tool for achieving meaningful learning in medical physiology students. Adv Physiol Educ. 2008;32: 312–316. pmid:19047509
85. Joshi V, Kulkarni AA. Public awareness of clinical trials: A qualitative pilot study in Pune. Perspect Clin Res. 2012;3: 125–32. pmid:23293759
86. Choi YJ, Beck S-H, Kang WY, Yoo S, Kim S-Y, Lee JS, et al. Knowledge and Perception about Clinical Research Shapes Behavior: Face to Face Survey in Korean General Public. J Korean Med Sci. 2016;31: 674–81. pmid:27134486
87. Bosnjak Pasic M, Vidrih B, Sarac H, Pasic H, Vujevic L, Soldo Koruga A, et al. Clinical Trials in Developing Countries—Ethical Considerations. Psychiatr Danub. 2018;30: 285–291. pmid:30267519
88. Tohid H, Choudhury SM, Agouba S, Aden A, Ahmed LHM, Omar O, et al. Perceptions and attitudes to clinical research participation in Qatar. Contemp Clin Trials Commun. 2017;8: 241–247. pmid:29696215
89. Kravitz RL, Paterniti DA, Hay MC, et al. Marketing therapeutic precision: potential facilitators and barriers to adoption of n-of-1 trials. Contemp Clin Trials. 2009;30(5):436–445.
90. Stocks N, Allan J, Frank O, Williams S, Ryan P. Improving attendance for cardiovascular risk assessment in Australian general practice: an RCT of a monetary incentive for patients. BMC Fam Pract. 2012;13: 54. pmid:22681743
91. BeLue R, Taylor-Richardson KD, Lin J, Rivera AT, Grandison D. African Americans and participation in clinical trials: differences in beliefs and attitudes by gender. Contemp Clin Trials. 2006 Dec;27(6):498-505.

**Supplementary Files**

This is a list of supplementary files associated with this preprint. Click to download.

- SupplementaryMaterialAdditionalFile2.docx
- SupplementaryMaterialAdditionalFile1.docx